Oral Magnesium Supplementation in Chronic Kidney Disease Stages 3 and 4: Efficacy, Safety, and Effect on Serum Calcification Propensity-A Prospective Randomized Double-Blinded Placebo-Controlled Clinical Trial

Iain Bressendorff; Ditte Hansen; Morten Schou; Burton Silver; Andreas Pasch; Pierre Bouchelouche; Lise Pedersen; Lars Melholt Rasmussen; Lisbet Brandi

doi:10.1016/j.ekir.2016.12.008

Oral Magnesium Supplementation in Chronic Kidney Disease Stages 3 and 4: Efficacy, Safety, and Effect on Serum Calcification Propensity-A Prospective Randomized Double-Blinded Placebo-Controlled Clinical Trial

Iain Bressendorff, Ditte Hansen, Morten Schou, Burton Silver, Andreas Pasch, Pierre Bouchelouche, Lise Pedersen, Lars Melholt Rasmussen, Lisbet Brandi

Institut for Klinisk Medicin

39 Citationer (Scopus)

49 Downloads (Pure)

Abstract

Introduction Chronic kidney disease (CKD) is associated with high cardiovascular morbidity and mortality. Recent evidence suggests that increases in both serum and intracellular magnesium (Mg) can slow or even prevent the development of vascular calcification seen in CKD. Serum calcification propensity (T₅₀) is a novel functional test, which is associated with all-cause mortality in CKD and measures the ability of serum to delay the formation of crystalline nanoparticles. Theoretically, increasing serum Mg should improve T₅₀ and thereby reduce the propensity towards ectopic calcification. Methods We conducted a randomized placebo-controlled double-blinded clinical trial to investigate the safety of 2 different doses of oral Mg supplementation in subjects with CKD stages 3 and 4 as well as their effects on intracellular Mg and T₅₀. Thirty-six subjects with CKD stages 3 and 4 were randomized to one of 3 groups (placebo, elemental Mg 15 mmol/d or elemental Mg 30 mmol/d) given as slow-release Mg hydroxide and followed for 8 weeks. Results Thirty-four subjects completed the trial. Intracellular Mg remained stable throughout the trial despite significant increases in both serum and urine Mg. T₅₀ increased significantly by 40 min from 256 ± 60 (mean ± SD) to 296 ± 64 minutes (95% confidence interval, 11–70, P < 0.05) in the Mg 30 mmol/d group after 8 weeks. No serious adverse events related to the study medication were reported during the study. Discussion Oral Mg supplementation was safe and well tolerated in CKD stages 3 and 4 and improved T₅₀, but did not increase intracellular Mg. Further studies are needed to investigate the long-term effects of Mg supplementation in CKD stage 3 and 4 and whether improvement in calcification propensity is related to clinical endpoints.

Originalsprog	Engelsk
Tidsskrift	Kidney International Reports
Vol/bind	2
Udgave nummer	3
Sider (fra-til)	380-389
ISSN	2468-0249
DOI	https://doi.org/10.1016/j.ekir.2016.12.008
Status	Udgivet - 1 maj 2017

Adgang til dokumentet

10.1016/j.ekir.2016.12.008Licens: CC BY-NC-ND

Oral Magnesium Supplementation in Chronic Kidney Disease Stages 3 and 4Forlagets udgivne version, 473 KBLicens: CC BY-NC-ND

Fingeraftryk

Dyk ned i forskningsemnerne om 'Oral Magnesium Supplementation in Chronic Kidney Disease Stages 3 and 4: Efficacy, Safety, and Effect on Serum Calcification Propensity-A Prospective Randomized Double-Blinded Placebo-Controlled Clinical Trial'. Sammen danner de et unikt fingeraftryk.

Citationsformater

Bressendorff, I., Hansen, D., Schou, M., Silver, B., Pasch, A., Bouchelouche, P., Pedersen, L., Rasmussen, L. M., & Brandi, L. (2017). Oral Magnesium Supplementation in Chronic Kidney Disease Stages 3 and 4: Efficacy, Safety, and Effect on Serum Calcification Propensity-A Prospective Randomized Double-Blinded Placebo-Controlled Clinical Trial. Kidney International Reports, 2(3), 380-389. https://doi.org/10.1016/j.ekir.2016.12.008

Oral Magnesium Supplementation in Chronic Kidney Disease Stages 3 and 4: Efficacy, Safety, and Effect on Serum Calcification Propensity-A Prospective Randomized Double-Blinded Placebo-Controlled Clinical Trial. / Bressendorff, Iain; Hansen, Ditte; Schou, Morten et al.
I: Kidney International Reports, Bind 2, Nr. 3, 01.05.2017, s. 380-389.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Bressendorff, I, Hansen, D, Schou, M, Silver, B, Pasch, A, Bouchelouche, P, Pedersen, L, Rasmussen, LM & Brandi, L 2017, 'Oral Magnesium Supplementation in Chronic Kidney Disease Stages 3 and 4: Efficacy, Safety, and Effect on Serum Calcification Propensity-A Prospective Randomized Double-Blinded Placebo-Controlled Clinical Trial', Kidney International Reports, bind 2, nr. 3, s. 380-389. https://doi.org/10.1016/j.ekir.2016.12.008

Bressendorff I, Hansen D, Schou M, Silver B, Pasch A, Bouchelouche P et al. Oral Magnesium Supplementation in Chronic Kidney Disease Stages 3 and 4: Efficacy, Safety, and Effect on Serum Calcification Propensity-A Prospective Randomized Double-Blinded Placebo-Controlled Clinical Trial. Kidney International Reports. 2017 maj 1;2(3):380-389. doi: 10.1016/j.ekir.2016.12.008

@article{92dafc1254b44e80adef30cf05f94477,

title = "Oral Magnesium Supplementation in Chronic Kidney Disease Stages 3 and 4: Efficacy, Safety, and Effect on Serum Calcification Propensity-A Prospective Randomized Double-Blinded Placebo-Controlled Clinical Trial",

abstract = "Introduction Chronic kidney disease (CKD) is associated with high cardiovascular morbidity and mortality. Recent evidence suggests that increases in both serum and intracellular magnesium (Mg) can slow or even prevent the development of vascular calcification seen in CKD. Serum calcification propensity (T50) is a novel functional test, which is associated with all-cause mortality in CKD and measures the ability of serum to delay the formation of crystalline nanoparticles. Theoretically, increasing serum Mg should improve T50 and thereby reduce the propensity towards ectopic calcification. Methods We conducted a randomized placebo-controlled double-blinded clinical trial to investigate the safety of 2 different doses of oral Mg supplementation in subjects with CKD stages 3 and 4 as well as their effects on intracellular Mg and T50. Thirty-six subjects with CKD stages 3 and 4 were randomized to one of 3 groups (placebo, elemental Mg 15 mmol/d or elemental Mg 30 mmol/d) given as slow-release Mg hydroxide and followed for 8 weeks. Results Thirty-four subjects completed the trial. Intracellular Mg remained stable throughout the trial despite significant increases in both serum and urine Mg. T50 increased significantly by 40 min from 256 ± 60 (mean ± SD) to 296 ± 64 minutes (95% confidence interval, 11–70, P < 0.05) in the Mg 30 mmol/d group after 8 weeks. No serious adverse events related to the study medication were reported during the study. Discussion Oral Mg supplementation was safe and well tolerated in CKD stages 3 and 4 and improved T50, but did not increase intracellular Mg. Further studies are needed to investigate the long-term effects of Mg supplementation in CKD stage 3 and 4 and whether improvement in calcification propensity is related to clinical endpoints.",

author = "Iain Bressendorff and Ditte Hansen and Morten Schou and Burton Silver and Andreas Pasch and Pierre Bouchelouche and Lise Pedersen and Rasmussen, {Lars Melholt} and Lisbet Brandi",

year = "2017",

month = may,

day = "1",

doi = "10.1016/j.ekir.2016.12.008",

language = "English",

volume = "2",

pages = "380--389",

journal = "Kidney International Reports",

issn = "2468-0249",

publisher = "Elsevier",

number = "3",

}

TY - JOUR

T1 - Oral Magnesium Supplementation in Chronic Kidney Disease Stages 3 and 4

T2 - Efficacy, Safety, and Effect on Serum Calcification Propensity-A Prospective Randomized Double-Blinded Placebo-Controlled Clinical Trial

AU - Bressendorff, Iain

AU - Hansen, Ditte

AU - Schou, Morten

AU - Silver, Burton

AU - Pasch, Andreas

AU - Bouchelouche, Pierre

AU - Pedersen, Lise

AU - Rasmussen, Lars Melholt

AU - Brandi, Lisbet

PY - 2017/5/1

Y1 - 2017/5/1

N2 - Introduction Chronic kidney disease (CKD) is associated with high cardiovascular morbidity and mortality. Recent evidence suggests that increases in both serum and intracellular magnesium (Mg) can slow or even prevent the development of vascular calcification seen in CKD. Serum calcification propensity (T50) is a novel functional test, which is associated with all-cause mortality in CKD and measures the ability of serum to delay the formation of crystalline nanoparticles. Theoretically, increasing serum Mg should improve T50 and thereby reduce the propensity towards ectopic calcification. Methods We conducted a randomized placebo-controlled double-blinded clinical trial to investigate the safety of 2 different doses of oral Mg supplementation in subjects with CKD stages 3 and 4 as well as their effects on intracellular Mg and T50. Thirty-six subjects with CKD stages 3 and 4 were randomized to one of 3 groups (placebo, elemental Mg 15 mmol/d or elemental Mg 30 mmol/d) given as slow-release Mg hydroxide and followed for 8 weeks. Results Thirty-four subjects completed the trial. Intracellular Mg remained stable throughout the trial despite significant increases in both serum and urine Mg. T50 increased significantly by 40 min from 256 ± 60 (mean ± SD) to 296 ± 64 minutes (95% confidence interval, 11–70, P < 0.05) in the Mg 30 mmol/d group after 8 weeks. No serious adverse events related to the study medication were reported during the study. Discussion Oral Mg supplementation was safe and well tolerated in CKD stages 3 and 4 and improved T50, but did not increase intracellular Mg. Further studies are needed to investigate the long-term effects of Mg supplementation in CKD stage 3 and 4 and whether improvement in calcification propensity is related to clinical endpoints.

AB - Introduction Chronic kidney disease (CKD) is associated with high cardiovascular morbidity and mortality. Recent evidence suggests that increases in both serum and intracellular magnesium (Mg) can slow or even prevent the development of vascular calcification seen in CKD. Serum calcification propensity (T50) is a novel functional test, which is associated with all-cause mortality in CKD and measures the ability of serum to delay the formation of crystalline nanoparticles. Theoretically, increasing serum Mg should improve T50 and thereby reduce the propensity towards ectopic calcification. Methods We conducted a randomized placebo-controlled double-blinded clinical trial to investigate the safety of 2 different doses of oral Mg supplementation in subjects with CKD stages 3 and 4 as well as their effects on intracellular Mg and T50. Thirty-six subjects with CKD stages 3 and 4 were randomized to one of 3 groups (placebo, elemental Mg 15 mmol/d or elemental Mg 30 mmol/d) given as slow-release Mg hydroxide and followed for 8 weeks. Results Thirty-four subjects completed the trial. Intracellular Mg remained stable throughout the trial despite significant increases in both serum and urine Mg. T50 increased significantly by 40 min from 256 ± 60 (mean ± SD) to 296 ± 64 minutes (95% confidence interval, 11–70, P < 0.05) in the Mg 30 mmol/d group after 8 weeks. No serious adverse events related to the study medication were reported during the study. Discussion Oral Mg supplementation was safe and well tolerated in CKD stages 3 and 4 and improved T50, but did not increase intracellular Mg. Further studies are needed to investigate the long-term effects of Mg supplementation in CKD stage 3 and 4 and whether improvement in calcification propensity is related to clinical endpoints.

U2 - 10.1016/j.ekir.2016.12.008

DO - 10.1016/j.ekir.2016.12.008

M3 - Journal article

C2 - 29142966

SN - 2468-0249

VL - 2

SP - 380

EP - 389

JO - Kidney International Reports

JF - Kidney International Reports

IS - 3

ER -